{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-022390","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.603062+00:00","generated_at":"2026-06-23T09:36:38.159717+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%","bullets":["Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.","Full fiscal year revenue $56.2M, down 11.6% from $63.6M; operating income $2.7M vs $5.8M.","Full year diluted EPS $0.12 vs $0.25; net income $3.8M vs $8.0M.","Co-CEOs cite normalization after pandemic-driven safety stock and demand as reasons for decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-022390","json":"https://secwatch.observer/filing/0001437749-22-022390.json","markdown":"https://secwatch.observer/filing/0001437749-22-022390.md","text":"https://secwatch.observer/filing/0001437749-22-022390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922022390/0001437749-22-022390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922022390/inbp20220913_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:36:38.159717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}